Figure 5.

Bufrolin suppresses LXR-mediated lipid accumulation in hepatocytes from wild-type mice. Hepatocytes (scale bar = 100 μm) from wild-type mice were exposed to T0901317, T0901317/bufrolin, or bufrolin alone. Lipid content was then measured. (A) Representative images visualized (BUF = bufrolin = 1 × 10^–5 M). (B) Oil Red O was solubilized and quantified by measuring absorbance at 510 nm, p < 0.05 a: versus vehicle, b: versus T0901317. The effect of varying concentrations of bufrolin (EC₅₀ = 7.9 ± 0.06 × 10^–8 M) is shown (C). Data are mean ± SEM, n = 3 (B, C). (D) Hepatocytes from GPR35 knock-out mice were treated as in (B) with T0901317, T0901317/bufrolin, or bufrolin alone, except that treatment with the ligands was for 5 days because a significant effect of T0901317 was not observed by treatment for 48 h. a: p < 0.05 versus vehicle. No significant difference (p > 0.05) was recorded between hepatocytes treated with T0901317 and T0901317/bufrolin.